When pharmaceutical innovator Sunovion sought to expand the number of products it offers for treating chronic obstructive pulmonary disease (COPD), it relied on experienced counsel from Holland & Knight in its $430 million acquisition of Elevation Pharmaceuticals, a privately held biopharmaceutical company specializing in aerosol therapies for individuals with respiratory diseases.
During the course of this multifaceted acquisition, we guided Sunovion through an extended and complex auction process, days of in-person negotiations and the amending of critical license agreements with third parties.
The products acquired by Sunovion include Elevation's EP-101, an inhaler solution for patients with COPD that is in Phase 2b clinical trials. This is an important and highly competitive market, and the transaction significantly strengthens Sunovion's position as a leader in providing effective therapeutic treatments to patients with life-threatening illnesses.
Complex transactions such as this one require broad-based legal counsel, and Holland & Knight was able to field a team of attorneys from across our many practices, including Mergers and Acquisitions; Healthcare & Life Sciences; Labor, Employment and Benefits; Taxation; Antitrust; Environment and Intellectual Property. The team took advantage of the firm's geographic reach and extensive transactional experience by calling on the skills of attorneys from several of our U.S. offices, including those in Miami, Tampa, Los Angeles, Washington, D.C., Fort Lauderdale, Tallahassee and Orlando.
Please note that email communications to the firm through this website do not create an attorney-client relationship between you and the firm. Do not send any privileged or confidential information to the firm through this website. Click "accept" below to confirm that you have read and understand this notice.